NADAC Chart of Prices

Brand

Generic

| Drug Name | NDC # | NADAC Per Unit | Effective Date of Last Update | Stock Size | Cost per Bottle |
|--|-------------|----------------|-------------------------------|------------|--------------------|
| Trileptal 300mg/ 5ml oral suspension | 00078035752 | 1.54309 | 12/22/21 | 250 ml | \$385.77 |
| Oxcarbazepine 300mg/5ml suspension | 50383031284 | 0.32558 | 6/22/22 | 250 ml | \$81.40 |
| | | | | | |
| Lamictal 25 mg tablet | 00173063302 | 14.18492 | 1/1/22 | 100 ct | \$1,414.92 |
| Lamotrigine 25 mg tablet | 16714070001 | 0.03422 | 6/22/22 | 100 ct | \$3.42 |
| | | | | | |
| Lamictal 100 mg tablet | 00173064255 | 16.20508 | 1/1/22 | 100 ct | \$1,620.51 |
| Lamotrigine 100 mg tablet | 16714070101 | 0.06241 | 6/22/22 | 100 ct | \$6.24 |
| | | | | | |
| Lamictal 150 mg tablet | 00173064360 | 17.81875 | 1/1/22 | 60 ct | \$1,069.13 |
| Lamotrigine 150 mg tablet | 16714070201 | 0.08563 | 6/22/22 | 60 ct | \$5.14 |
| | | | | | |
| Lamictal 200 mg tablet | 00173064460 | 19.36280 | 1/1/22 | 60 ct | \$1,161.77 |
| Lamotrigine 200 mg tablet | 16714070301 | 0.10072 | 6/22/22 | 60 ct | \$6.15 |

The National Average Drug Acquisition Cost (NADAC) is based on a retail price survey of actual community pharmacy acquisition costs. The Centers for Medicare and Medicaid Services (CMS) has mandated that Medicaid pharmacy programs reimburse the actual acquisition cost (AAC) of drugs plus a professional dispensing fee. The NADAC represents the average acquisition cost and the pharmacies surveyed include independent retail and community pharmacies as well as chain pharmacies.

NADAC files are updated on a weekly basis. Each month, a new file is posted to reflect findings from the previous month's survey results incorporating the weekly price changes that have occurred in the interim weeks before the next monthly NADAC file. NADAC weekly files as well as file comparisons can be found at https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/index.html.

Pharmacies are also allowed to ask for pricing reviews if they find their acquisition costs have increased and do not match current NADAC pricing. Many times, claims can be rebilled retroactively if pricing is updated to match current market pricing.

